Abstract
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have